152 related articles for article (PubMed ID: 18512272)
1. Open label trial of alefacept in palmoplantar pustular psoriasis.
Carr D; Tusa MG; Carroll CL; Pearce DJ; Camacho F; Kaur M; Cook C; Willard J; McCarty A; Fleischer AB; Liu CM; Goffe BS; Feldman SR
J Dermatolog Treat; 2008; 19(2):97-100. PubMed ID: 18512272
[TBL] [Abstract][Full Text] [Related]
2. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis.
Prossick TA; Belsito DV
Cutis; 2006 Sep; 78(3):178-80. PubMed ID: 17036660
[TBL] [Abstract][Full Text] [Related]
3. Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis.
Moul DK; Routhouska SB; Korman NJ
J Cutan Med Surg; 2007; 11(4):132-6. PubMed ID: 17601420
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
[TBL] [Abstract][Full Text] [Related]
5. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
[TBL] [Abstract][Full Text] [Related]
6. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis.
Cafardi JA; Cantrell W; Wang W; Elmets CA; Elewski BE
Skinmed; 2008; 7(2):67-72. PubMed ID: 18327010
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic hotline. Alefacept in the treatment of hyperkeratotic palmoplantar psoriasis.
Lior S; Grigory K; Pnina S; Joseph S; Felix P
Dermatol Ther; 2010; 23(5):556-60. PubMed ID: 20868412
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
Gottlieb A; Sullivan J; van Doorn M; Kubanov A; You R; Parneix A; Hugot S; Milutinovic M
J Am Acad Dermatol; 2017 Jan; 76(1):70-80. PubMed ID: 27707593
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept.
Weinberg JM
Cutis; 2003 Nov; 72(5):396-8. PubMed ID: 14655781
[TBL] [Abstract][Full Text] [Related]
12. Alefacept in the treatment of psoriasis.
Sugiyama H; McCormick TS; Cooper KD; Korman NJ
Clin Dermatol; 2008; 26(5):503-8. PubMed ID: 18755368
[TBL] [Abstract][Full Text] [Related]
13. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study.
Reich K; Graff O; Mehta N
Br J Dermatol; 2016 Jun; 174(6):1277-81. PubMed ID: 26800106
[TBL] [Abstract][Full Text] [Related]
14. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis.
Krell J; Nelson C; Spencer L; Miller S
J Am Acad Dermatol; 2008 Apr; 58(4):609-16. PubMed ID: 18262681
[TBL] [Abstract][Full Text] [Related]
15. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: interim results of a single-arm, open-label study.
Gattu S; Busse K; Bhutani T; Chiang C; Nguyen T; Becker E; Koo JY
J Dermatolog Treat; 2012 Apr; 23(2):103-8. PubMed ID: 21254875
[TBL] [Abstract][Full Text] [Related]
17. Complete response of secukinumab in palmoplantar psoriasis.
Rocamora V; Garcías-Ladaria J
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469799
[TBL] [Abstract][Full Text] [Related]
18. An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept.
Magliocco MA; Lozano AM; Van Saders C; Schuler KW; Gottlieb AB
J Drugs Dermatol; 2007 Apr; 6(4):424-7. PubMed ID: 17668540
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis.
Khandpur S; Sharma VK
Clin Exp Dermatol; 2011 Aug; 36(6):613-6. PubMed ID: 21507036
[TBL] [Abstract][Full Text] [Related]
20. An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum.
Foss CE; Clark AR; Inabinet R; Camacho F; Jorizzo JL
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):943-9. PubMed ID: 18384543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
